Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124123 | 0.75 | APLNR (0.32) | — | |
| SCHEMBL25522602 | 0.73 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL5950443 | 0.72 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL23844419 | 0.71 | APLNR (0.30) | — | |
| SCHEMBL14804005 | 0.70 | — | — | |
| SCHEMBL23844601 | 0.70 | — | — | |
| SCHEMBL12500833 | 0.69 | — | — | |
| SCHEMBL17716525 | 0.69 | TP53 (0.31) | — | |
| SCHEMBL18174957 | 0.69 | CYP3A4 (0.38) | — | |
| SCHEMBL2629415 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-11530207-B2 | Compounds for the treatment of cancer | SKYHAWK THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210292316-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | SKYHAWK THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-9893300-B1 | Phenanthroimidazole compound and organic light-emitting diode including the same | NATIONAL TSING HUA UNIVERSITY (TW) | 2018-02-13 | — | — | US | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150099738-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | NOS3 3085/4885NOS1 3464/4885NOS2 3496/4885 |
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | NOS3 3731/4885NOS1 3973/4885NOS2 3807/4885 |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | NOS3 491/4885NOS1 367/4885NOS2 624/4885 |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS3 4452/4885NOS1 4159/4885NOS2 4563/4885 |
| US-11530207-B2 | Compounds for the treatment of cancer | SNRPE, HNRNPUL2, HNRNPM | NOS3 2198/4885NOS1 2439/4885NOS2 2490/4885 |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS3 4061/4885NOS1 3507/4885NOS2 4038/4885 |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | NOS3 491/4885NOS1 367/4885NOS2 624/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | NOS3 1085/4885NOS1 673/4885NOS2 1555/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS3 4019/4885NOS1 4104/4885NOS2 4517/4885 |
| US-20150099738-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | NOS3 1790/4885NOS1 1881/4885NOS2 1665/4885 |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | NOS3 2960/4885NOS1 2185/4885NOS2 2535/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | NOS3 2485/4885NOS1 2004/4885NOS2 2249/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS3 4253/4885NOS1 4348/4885NOS2 4647/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | NOS3 279/4885NOS1 379/4885NOS2 881/4885 |
| US-20210292316-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | SNRPE, HNRNPUL2, HNRNPM | NOS3 2198/4885NOS1 2439/4885NOS2 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.